Abstract Body

The SALSA study showed switching to DTG/3TC FDC was non-inferior to continuing current antiretroviral regimen (CAR) at Week 48, with 94% (232/246) vs 93% (229/247) having HIV-1 RNA viral load (VL) <50 c/mL by FDA Snapshot algorithm. This post-hoc analysis assesses proportion of baseline (BL) participant samples with archived resistance, and virologic response through 48 weeks using the stringent VL measure <40 c/mL and target not detected (TND).

Adults with VL <50 c/mL for ?6 months without evidence of virologic failure were randomized to DTG/3TC FDC or continued CAR. Historic genotypic resistance results were submitted if available, and participants were excluded if IAS 2019 DTG-associated or major NRTI resistance was present. RealTime HIV-1 assay provided quantitative VL from 40 to 10,000,000 c/mL, and qualitative target detected (TD) or TND data for VL <40 c/mL. TND at last available on-treatment VL was assessed for participants with BL proviral genotype data from Monogram Biosciences Genosure Archive assay, at least 1 post-BL on-treatment VL result, and not meeting protocol deviation.

Of 246 and 247 participants randomized to the DTG/3TC and CAR groups, respectively, BL proviral DNA genotypes were generated for 196/224 and 189/216 available samples. Time from first ART to study start for those with BL genotypes available (excluding 4 protocol deviators per arm) was [median (range)] 66.1 (4,240) and 74.4 (12,253) months. Overall proportions with TND at last available on-treatment VL in DTG/3TC and CAR groups were 155/192 (81%) and 153/185 (83%), respectively. Participants in the DTG/3TC and CAR groups, respectively, had 15 (8%) vs 16 (9%) major NRTI mutations, 28 (15%) vs 17 (9%) major NNRTI, 14 (7%) vs 12 (6%) major PI, 1 (<1%) vs 4 (2%) major INSTI, and 8 (4%) vs 5 (3%) minor INSTI mutations. Frequencies for TND through 48 weeks by BL mutation were broadly similar across groups (Table). M184V/I was present in 5 (3%) participants in both the DTG/3TC and CAR groups, all with VL <40 c/mL and, respectively, 4/5 vs 3/5 having VL <40 c/mL and TND at Week 48.

Using a more stringent measure of VL <40 c/mL and TND, responses for DTG/3TC vs CAR were similar despite BL archived proviral resistance, including M184V/I present in BL testing at 3%. These data, as well as prior reported responses using <50 c/mL for DTG/3TC vs CAR (SALSA) or TAF-based regimen (TANGO study), are supportive of the efficacy and potency of DTG/3TC in suppressed switch participants.